Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $2.39 million versus the consensus estimate of $1.22 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.